Core Viewpoint - The announcement details the implementation of the 2024 Restricted Stock Incentive Plan by Shenzhen Meihua Chuangyi Medical Technology Co., Ltd, highlighting the first vesting results and the listing of shares [1][19]. Summary by Relevant Sections Stock Incentive Plan Overview - The total number of shares for this vesting is 1,236,792 shares, accounting for 0.30% of the company's total share capital [1]. - The number of participants in this vesting is 154 individuals [1]. - The shares are sourced from A-shares repurchased by the company from the secondary market [1]. Vesting Conditions and Arrangements - The first vesting period is set to begin on May 9, 2025, and will last until the last trading day within 24 months from the grant date [10]. - The vesting arrangement includes three periods: - First vesting period: 30% after 12 months - Second vesting period: 30% after 24 months - Third vesting period: 40% after 36 months [4][5]. Performance Assessment - The performance assessment for the first vesting period is based on the company's revenue and net profit growth rates, with specific target and trigger values set for 2024-2026 [5][10]. - The company achieved a revenue growth rate of 19.19% in 2023, with a net profit growth rate of 22.09% [10]. Adjustments and Cancellations - A total of 481,198 shares were canceled due to participants leaving the company and performance not meeting target values [9][11]. - The adjusted grant price for the shares is set at 12.26 yuan per share [8][14]. Listing and Trading Restrictions - The shares will be listed for trading on May 16, 2025 [15]. - There are restrictions on the transfer of shares held by directors and senior management, in accordance with relevant regulations [16]. Financial and Legal Compliance - The company has complied with necessary legal and regulatory requirements for the implementation of the incentive plan [18][19]. - The independent financial advisor confirmed that the plan's adjustments and vesting conditions have been properly reviewed and disclosed [18].
美好医疗: 关于2024年限制性股票激励计划首次授予第一个归属期归属结果暨股份上市的公告